MXPA98009513A - Derivatives of 2,4-diaminopiridine - Google Patents

Abstract

The present invention relates to compounds of the general formula I wherein R 1 signifies lower alkoxy, R 2 means lower alkoxy bromo or hydroxy, R 3 signifies hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl or cyano, R 4 and R 5 mean each, independently, hydrogen, lower alkyl, lower alkoxy, halogen, hydroxy, amino, di (lower alkyl) -amino, cyano or nitro and Q means ethynylene or vinylene, their pharmaceutically usable salts, the use of these compounds and their salts as therapeutically active substances, drugs based on these substances and their production, the use of these substances as medicaments and for the production of antibacterially active medicaments, as well as the preparation of the compounds of formula (I) and their pharmaceutically acceptable salts and intermediaries for its preparation

Description

DERIVATIVES OF 2, 4-DIAMINOPIRIMIDINA FIELD OF THE INVENTION The present invention relates to substituted 2,4-diaminopyrimidines of the general formula wherein R means lower alkoxy, R 2 signifies bromine, lower alkoxy or hydroxy, R 3 signifies hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl or cyano, R 4 and R 5 signify each, independently, hydrogen, lower alkyl, alkoxy lower, halogen, hydroxy, amino, di (lower alkyl) -amino, cyano or nitro and Q means ethynylene or vinylene, as well as their pharmaceutically usable salts.

BACKGROUND OF THE INVENTION These compounds are new and have valuable REF .: 28754 antibiotic properties. They can be used for the control or prevention of infectious diseases. In particular, they exhibit pronounced antibacterial activity, even against multiresistant Gram-positive strains, and against opportunistic pathogens such as, for example, Pneumocystis carinii. These compounds can also be administered in combination with known antibacterially active substances and then exhibit synergistic effects. Typical combination partners are, for example, sulfonamides, with which the compounds of the formula I or their salts can be mixed in various ratios.

DESCRIPTION OF THE INVENTION Objects of the present invention are the compounds of formula I and their pharmaceutically acceptable salts per se and for use as therapeutically active substances; medicines based on these substances, optionally in combination with sulfonamides, and their production; the use of these substances as medicines and for the production of antibacterially-active drugs; as well as the preparation of the compounds of formula I and their pharmaceutically acceptable salts and intermediates for their preparation. The term "lower" used herein means a straight or branched chain group with 1-6 carbon atoms. Examples of lower alkyl are methyl, ethyl, n-propyl, isopropyl, n-butyl, sec. I use, isobutyl, ter. utilo, n-pentyl and n-hexyl; Examples of lower alkoxy are correspondingly methoxy, ethoxy, n-propoxy, isopropoxy and t-butoxy. Low "Cycloalkyl" is to be understood as meaning cyclic alkyl groups with preferably 3-6 carbon atoms. The term "halogen" encompasses fluorine, chlorine, bromine and iodine. The term "aryl" denotes mono- or polynuclear 6-membered aromatic groups with, preferably, 6-14 carbon atoms. Examples are phenyl, naphthyl, anthryl and phenanthryl. These groups can be substituted, for example by phenyl; lower alkyl (for example methyl); C3-6 cycloalkyl (for example cyclopropyl); halogen (for example chlorine); trifluoromethyl; lower alkoxy (for example methoxy, n-butoxy); lower alkoxycarbonyl (for example methoxycarbonyl); hydroxy; di (lower alkyl) amino (for example dimethylamino, diethylamino); cyano; carbamoyl, mono- or di-lower alkylcarbamoyl; lower alkylsulfanyl, for example methylsulfanyl; lower alkylsulfonyl, for example methanesulfonyl; sulfamoyl, N-mono- or di-lower alkylsulfamoyl; heteroaryl, for example morpholin-4-yl, 4-methyl-piperazin-1-yl, imidazol-1-yl and [1, 2, 4] triazol-1-yl; heteroaryl-lower alkyl, for example morpholin-4-ylmethyl, 4-methyl-piperazin-1-ylmethyl, imidazol-1-ylmethyl and [1, 2, 4] triazol-1-ylmethyl, (cycloalkyl) amino; a residue or radical (CH2) 0-6-N-Het, where Het means the radical of an N-heterocyclic ring, which may contain an oxygen or sulfur atom or NH or N-lower alkyl as a ring element; or tetrazolyl. "Heteroaryl" denotes heteroaromatic mono- or polynuclear groups of 5 or 6 elements, preferably 5-13 carbon atoms and 1-4 heteroatoms, preferably N, 0 and / or 5. Examples are furyl, pyranyl, thienyl, pyrrolyl pyrazolyl, imidazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl. These groups can also be linked to a fused ring, preferably a phenyl ring, such as benzopyranyl, benzofuranyl, indolyl and quinolinyl. The heteroaryl groups can also be further substituted, for example, as described above for the aryl groups. Q is preferably vinylene. Preferred compounds of formula I are those wherein R1 and R2 mean lower alkoxy, especially methoxy; R3 means substituted phenyl, or pyridyl, especially 2- or 3-pyridyl or substituted pyridyl, or thienyl; R4 means hydrogen; and Rs means hydrogen or lower alkoxy, especially methoxy. The compounds of formula I in which R3 is not hydrogen may be present in racemic form or as the R- or S-enantiomer. Examples of preferred compounds of formula I are: (E) - (R) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- (l- pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, (Example 1); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridin-2-yl-3, 4 -dihydro-lH-isoquinolin-2-yl) -propenone, (Example 3); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (7-methoxy-l-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl) -propenone, (Example 8); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methyl-phenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 16); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-hydroxy-phenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 21); (E) - (RS) -1- (1-cyclopropyl-3,4-dihydro-1H-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2 , 3-dimethoxyphenyl] -propenone, (Example 22); (E) - (RS) -4- [2- [3- [5- (2,4-diamino-pyrimidin-5-yl) -2,3-dimethoxy-phenyl] -acryloyl] -1,2,3 , 4-tetrahydro-isoquinolin-1-yl] -benzonitrile, (Example 23); (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- (1-thiophen-2-yl-3, 4 -dihydro-lH-isoquinolin-2-yl) -propenone, (Example 27); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) - > 2, 3-dimethoxy-phenyl] -1- [1- (6-methyl-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 32); (E) - (RS) -l- [l- (5-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4- diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, (Example 34); (E) - (RS) -1- [1- (6-chloro-pyridin-3-yl) -3,4-dihydro-l-isoquinolin-2-yl] -3- [5- (2, 4- diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, (Example 36); (E) - (RS) -5- [2- [3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1,2,3 , 4-tetrahydro-isoquinolin-1-yl] -pyridine-2-carboxamide, (Example 39); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (4-methanesulfonyl-phenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 40); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (4-dimethylamino-pyridin-2- il) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 44); (E) - (RS) -4- (2- { 3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl}. , 2, 3, 4-tetrahydro-isoquinolin-1-yl) -benza ida, (Example 49); (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (4-methylsulfanyl-phenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 55); and (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2, 5-dimethyl-2H -pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 71); as well as pharmaceutically usable salts of these compounds. The compounds of the formula I form pharmaceutically acceptable acid addition salts with organic and inorganic acids. Examples of acid addition salts of compounds of formula I are salts with mineral acids, for example hydrohalic acids, such as hydrochloric acid, hydrogen bromide and hydrogen iodide, sulfuric acid, nitric acid, phosphoric acid, and the like, salts with organic sulfonic acids, for example with alkyl- and arylsulfonic acids such as methanesulfonic acid, p-toluenesulfonic acid, benzenesulfonic acid and the like, as well as salts with organic carboxylic acids, for example with acetic acid, tartaric acid, maleic acid, citric acid, benzoic acid, salicylic acid, ascorbic acid and the like. The compounds of formula I and their pharmaceutically acceptable salts can be prepared according to the invention by (a) reacting a compound of the general formula with a compound of the general formula wherein R1-R5 and Q have the meaning indicated above and Y represents a separation group, or b) if desired, functionally modifying reactive groups present in the reaction product, or c) converting a compound of formula I into a pharmaceutically acceptable salt.

In order to prepare final products of formula I according to variant a) of the process according to the invention, a so-called "Heck reaction" is carried out for example by reacting a starting material of formula II in which Y represents bromine, iodine, methanesulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy or p-toluenesulfonyloxy with a compound of general formula III. Preferably, an inert organic solvent is used, for example dioxane, tetrahydrofuran, N, N-dimethylacetamide or N, N-dimethylformamide. The reaction is preferably carried out in the presence of a base such as an alkali metal carbonate, for example potassium carbonate, or a tertiary amine, for example in a tri (lower alkyl) mine such as triethylamine or tri-n-butylamine, and together with a catalyst, preferably a palladium complex such as α-aladium (II) acetate, bis (triphenylphosphine) palladium (II) dichloride, bis (triphenylphosphine) palladium (II) diacetate, tetrakistriphenyl-phosphinepalladium, or iodide of copper (I) and triphenylphosphine or tri-o-tolylphosphine, optionally with the addition of a phase transfer catalyst, such as a tetraalkylammonium salt, for example, tetramethylammonium chloride. The temperature of the "Heck reaction" is found, preferably in the region between about 40 ° C and the boiling point of the reaction mixture. If desired, reactive groups present in the product of formula I can be functionally modified in accordance with variant b) of the process according to the invention. For example, R3 groups such as cyano or cyanophenyl can be converted into R3 groups such as tetrazolyl or tetrazolylphenyl. This reaction is carried out, for example, by treatment with sodium azide in N, N-dimethylformamide in the presence of ammonium chloride. The temperature is preferably between S0 ° C and 120 ° C, especially at 90 ° C. The preparation or production of the salts of the compounds of formula I according to variant c) can be carried out in a manner known per se, for example by reacting a compound of formula I with an organic or inorganic acid, conveniently in a solvent such as acetone, ethanol, methanol or water. The compounds of formula III can be obtained according to the invention by reacting a compound of the general formula R3 R < -cor '- in which R3-R5 have the meaning indicated above, with a reactive derivative of acrylic acid or propiolic acid. Examples of reactive derivatives of acrylic acid or propiolic acid are acid halides, especially chloride, reactive amides, such as imidazolide and mixed anhydrides. The acylation according to the invention can be carried out in an inert solvent, for example a hydrocarbon such as benzene or toluene, a chlorinated hydrocarbon such as chloroform or methylene chloride or an ether such as dioxane or tetrahydrofuran, in the presence of a base, for example an amine such as pyridine or triethylamine (which may simultaneously serve as the solvent). The reaction temperature is not critical. The reaction is conveniently carried out at temperatures between 0 ° C and 50 ° C, especially between 0 ° C and 30 ° C. The compounds of the formula III (Q = ethynylene) can be prepared, for example, according to the following Reaction Scheme: n B III wherein Q, R3, R4 and R5 have the meaning indicated above and M means -Li, -Na, -MgBr, -MgCl, or -Mgl.

Reaction to This reaction can be carried out according to methods that are known per se and will be familiar to anyone skilled in the art. Is carried out, preferably, by treatment with phosgene or with a phosgene substitute such as trichloromethyl chloroformate (diphosgene) or bis (trichloromethyl) carbonate (triphosgene). The chloroacylation according to the invention can be carried out in an inert solvent, for example a hydrocarbon such as benzene or toluene, a chlorinated hydrocarbon such as chloroform, methylene chloride or dichloroethane, or an ether such as dioxane or tetrahydrofuran, in the presence of a base, for example an amine such as pyridine or triethylamine (which can serve simultaneously, as the solvent). The reaction is carried out at temperatures between -20 ° C and 110 ° C, especially between 0 ° C and 50 ° C.

Reaction B This reaction is the production of a substituted urea derivative VI. It can be carried out following methods known per se by reacting a carbamoyl chloride V with an amine of the formula HNR6R7 or a salt of this amine. Preferably a chlorinated lower hydrocarbon such as chloroform or methylene chloride is used as the solvent. The reaction is preferably carried out in the presence of an organic base such as pyridine, triethylamine or 4-dimethyl-aminopyridine in a temperature range of -10 ° C to 60 ° C. The lower alkyl or lower alkoxy groups R6 and R7 are preferably methyl and methoxy.

Reaction C This reaction can be carried out following methods which are known per se and which will be familiar to any person skilled in the art. It is carried out, preferably in a temperature range of -80 ° C to 20 ° C. The symbol M means, preferably -MgBr. Preferably, an open-chain or cyclic ether such as i-ethyl ether, dimethoxyethane or tetrahydrofuran is used as the solvent. The starting materials of formulas II and IV are known or can be prepared as described in the Examples or analogously to these. As indicated above, the compounds of formula I and their pharmaceutically acceptable salts possess valuable antibacterial properties. They are active against a large number of pathogenic microorganisms such as, for example, Staphylococcus aureus, Pneumocystis carinii, etc., by virtue of their activity in inhibiting bacterial dihydrofolate reductase (DHFR). Inhibition of this enzyme was taken as a measure of antibacterial activity. It is determined with the method of D.P. Baccanari and S.S. Joyner (Biochemistry 20, 1710 (1981)); see also P.G. Hartman et al., FEBS Letters 242, 157 (1988). The IC 50 values (concentration with which the 50% enzyme is inhibited) are determined by means of a graph. The following Table contains inhibitory concentrations obtained for elements representative of the class of the compound defined by formula I and determined in the previous test. IC 50 (μM) values are offered against purified DHFR of the reference strain S. aureus ATCC 25923 as well as against the purified DHFR of the S. ureus multiresistant strain 157/4696. The third column shows the IC50 (μM) values against purified DHFR of opportunistic P. carinii pathogen. The inhibition constants of trimethoprim are also offered as a comparison.

EXAMPLES S. aureus S. aureus P. carinii ATCC 157/4696 25923 Trimethoprim 0.0340 16.0000 43.00 1 0.0050 0.0080 8.00 3 0.0090 0.0095 17.00 8 0.0050 0.0090 5.00 16 0.0002 0.0048 0.33 21 0.0055 0.0130 0.38 27 0.0016 0.0018 3.80 32 0.0018 0.0013 10.00 34 0.0024 0.0017 10.00 23 0.0005 0.0009 10.00 36 0.0008 0.0030 6.2 39 0.0012 0.0018 30.00 40 0.0007 0.0012 0.55 The products according to the invention can be used as medicaments, for example in the form of pharmaceutical preparations for enteral or parenteral administration. For example, the products according to the invention can be administered perorally, for example in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, for example in the form of suppositories, or parenterally , for example in the form of injection solutions. The production of the pharmaceutical preparations can be carried out in a way that will be familiar to any person skilled in the art carrying the substances according to the invention, optionally in combination with other therapeutically valuable substances, in a galenic administration form together with solid carrier materials or liquid, therapeutically compatible, inert, non-toxic, suitable, and, if desired, the usual pharmaceutical adjuvants. Both inorganic and organic carrier materials are suitable as vehicle materials. So that, for example, lactose, corn starch or its derivatives, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragees and hard gelatine capsules. Suitable vehicles for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient, however, vehicles are not required in the case of soft gelatine capsules). Suitable vehicle materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and glucose. Suitable carrier materials or carriers for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. The usual preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents and antioxidants come into consideration as pharmaceutical adjuvants. For parenteral administration the compounds of formula I and, respectively, their salts, are preferably provided as lyophilizates or dry powders for dilution with customary carriers such as water or isotonic saline.

As indicated above, the compounds of formula I and their salts have antibacterial activity. They inhibit bacterial dihydrofolate reductase and potentiate the antibacterial activity of sulfonamides such as, for example, sulfisoxazole, sulfadimethoxine, sulfamethoxazole, 4-sulfanilamido-5,6-dimethoxypyrimidine, 2-sulfanilamido-4,5-dimethylpyrimidine or sulfaquinoxaline, sulfadiazine, sulfamonomethoxine, 2 Sulfanilamido-4,5-dimethylisoxazole and other enzyme inhibitors which are involved in folic acid biosynthesis, such as, for example, pteridine derivatives. Human combinations for one or more compounds I according to the invention with sulfonamides, oral, rectal and parenteral administration are considered in human medicine. The ratio of compound I to sulfonamide can vary within a wide range; amounts for example between 1:40 (parts by weight) and 1: 1 (parts by weight); preferably the relationships are from 1:10 to 1: 2. Thus, for example, a tablet can contain 80 mg of a compound I according to the invention and 400 mg of sulfamethoxazole, a tablet for children can contain 20 mg of compound I according to the invention and 100 mg of sulfamethoxazole; Syrup (per 5 ml) may contain 40 mg of compound I and 200 mg of sulfamethoxazole. A daily dose of about 0.2 to about 2 g of a compound of formula I according to the invention is considered for adults. The compounds of formula I are characterized by a high antibacterial activity and a pronounced synergistic effect in combination with sulfonamides and are well tolerated. The following examples illustrate the invention in greater detail.

EXAMPLE 1 7.74 g of (R) -1- (l-pyridin-2-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone in 30 ml of N, N-dimethylacetamide was treated with 9.65 g of - (3-iodo-4,5-dimethoxy-benzyl) -pyrimidine-2,4-diamine, 112 mg of palladium (II) acetate, 608 mg of tri-o-tolylphosphine as well as 4.3 ml of triethylamine and stir at 120 ° C for 25 minutes. Drops were added while stirring 150 ml of a 10% sodium bicarbonate solution to the reaction mixture that had cooled to room temperature. The reaction mixture was then treated with 100 ml of dichloromethane and stirred for a further 10 minutes. The phases were separated and the aqueous phase was extracted with 30 ml of dichloromethane. From the combined dichloromethane phases, after drying over sodium sulfate and concentration, 19 g of a pale orange foam was obtained which was chromatographed on 250 g of silica gel using the eluent dichloromethane-methanol-25% ammonia . The pure fractions were combined and concentrated. Recrystallization of the yellowish residue (10.85 g) in acetonitrile / ethanol gave 9.54 g of (E) - (R) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy- phenyl] -1- (l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone in the form of a beige product, melting point 136-140 ° C. In analogous manner to Example 1, the following compounds were prepared: EXAMPLES 2-70 2. (E) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (3,4-dihydro-lH-isoquinolin-2-yl) - propenone, melting point 110-112 ° C, dec. (ethanol). 3. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridin-2-yl-3) , 4-dihydro-lH-isoquinolin-2-yl) -propenone, mp 193-196 ° C (acetonitrile). 4. (E) -1- (7-Chloro-3,4-dihydro-lH-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3 -dimethoxy-phenyl] -propenone, melting point 157-160 ° C. 5. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-phenyl-3,4-dihydro) -lH-isoquinolin-2-yl) -propenone, melting point 155-160 ° C (acetonitrile). 6. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridin-4-yl-3) , 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 125-128 ° C (water). 7. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-yl-methyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridin-3-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone , melting point 229 ° C (ethanol). 8. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (7-methoxy-1-pyridine-2) -yl-, 3,4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 167-169 ° C. 9. 3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (3,4-dihydro-lH-isoquinolin-2-yl) -propinone, melting point 113-116 ° C (chloroform / hexane). 10. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyrazin-2-yl-3) , 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 210-214 ° C (ethanol). 11. (E) - (RS) -1- (7-chloro-l-pyridin-2-yl-3,4-dihydro-lH-isoquinolin-2-yl) -3- [5- (2, 4-diamino- pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -propenone, melting point 195-196 ° C (ethanol). 12. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (7-methyl-1-pyridin-2) -yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 185-187 ° C (acetonitrile) 13. (E) - (RS) -1- [1- (4-chloro phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propeneone, point melting 148-150 ° C (1,2-dimethoxyethane). 14. (E) - (RS) -1- (1-cyclohexyl-3, 4-dihydro-1H-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxyphenyl] -propenone, melting point 203 ° C (ethanol). 15. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (1-pyrimidin-5-yl) hydrochloride -3,4-dihydro-lH-isoquinolin-2-yl) -propenone (1: 1.75), melting point 155 ° C, dec. (ethanol). 16. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 155-157 ° C (acetonitrile). 17. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyrimidin-4-yl-3 , 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 97 ° C, dec. (ethanol). 18. (E) - (RS) -1- (1-Benzyl-3, 4-dihydro-1H-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, melting point 107-120 ° C. 19. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-isobutyl-3,4-dihydro) -lH-isoquinolin-2-yl) -propenone, mp 107 ° C (ethanol). 20. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methoxy-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 191-194 ° C (acetonitrile). 21. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-hydroxy-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 170-172 ° C (acetonitrile). 22. (E) - (RS) -1- (1- (1-cyclopropyl-3,4-dihydro-1H-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidine-5 -ylmethyl) -2,3-dimethoxyphenyl] -propenone, mp 115-125 ° C (acetonitrile) 23. (E) - (RS) -4- [2- [3- [5- (2, 4 -diamino-pyrimidin-5-yl) -2, 3-dimethoxy-phenyl] -acryloyl] -1,2,3,4-tetrahydro-isoquinolin-1-yl] -benzonitrile, melting point 158-161 ° C ( acetonitrile) 24. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-dimethylamino phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 157-160 ° C (acetonitrile) 25. (E) - (RS) -3- [5- (2 , 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridazin-3-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propeneone, point melting point 128 ° C, dec. (ethanol / diethyl ether) 26. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy- phenyl] -1- (l-pyridazin-4-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, mp 122 ° C, dec. (MeOH / acetonitrile) 27. ( E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-thiophen-2-yl-3, 4- dihydro-lH-isoquinolin-2-yl) -propenone, melting point 116 ° C, dec. (ethanol / methanol). 28. (E) - (RS) -2- [3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1,2,3, 4-tetrahydro-isoquinoline-1-carbonitrile, melting point 226 ° C, dec. (methylene chloride / t-BuOMe). 29. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-trifluoromethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 155-157 ° C (acetonitrile).

. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (6-hydroxy-pyridine-) trifluoroacetate 3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone (1: 1), MS (ISP): 539.4 (M + H) +. 31. (E) - (RS) -4- [2- [3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1.2 3, 4-tetrahydroisoquinolin-1-yl] -benzoic acid ethyl ester, melting point 125-130 ° C (acetonitrile). 32. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (6-methyl-pyridine- 3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 205 ° C (acetonitrile). 33. (E) - (RS) -1- [1- (4-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, mp 141-145 ° C (acetonitrile). 34. (E) - (RS) -1- [1- (5-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, melting point 130-132 ° C (acetonitrile). 35. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (6-dimethylamino-pyridine- 3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 155-156 ° C (acetonitrile) 36. (E) - (RS) -l- [l- (6 -chloro-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy- phenyl] -propenone, melting point 157 ° C (ethanol). 37. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2-hydroxy-3-methoxy-phenyl] -1- (l-pyridin-2-yl. -3,4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 145-155 ° C (acetonitrile / ethanol). 38. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-diethylaminomethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 112-114 ° C (acetonitrile). 39. (E) - (R, S) -5- [2- [3- [5- (2, 4-diamino-pyrimid-din-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1, 2,3,4-tetrahydro-isoquinolin-1-yl] -pyridine-2-carboxamide, melting point 162-170 ° C (ethanol). 40. (E) - (R, S) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methanesulfonyl- phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 140-150 ° C (acetonitrile). 41. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methoxy-pyridin- 2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 232-235 ° C (ethanol / acetonitrile). 42. (E) - (RS) -5- (2- { 3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -7 1,2,3,4-tetrahydro-isoquinolin-1-yl) -pyridine-2-carboxamide, mp 162-170 ° C (ethanol). 43. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methanesulfonyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 140-150 ° C (acetonitrile). Four . (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (4-dimethylamino-pyridin-2- il) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 215-218 ° C (acetonitrile). 45. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (6-morpholin-4- il-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 137-145 ° C (acetonitrile). 46. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-fluoro-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 126-130 ° C (acetonitrile). 47. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1-. { 1- [6- (4-methyl-piperazin-1-yl) -pyridin-3-yl] -3,4-dihydro-1H-isoquinolin-2-yl} -propenone, mp 133-138 ° C (acetonitrile). 48. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-morpholin-4- ylmethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 118-125 ° C (acetonitrile). 49. (E) - (RS) -4- (2- { 3- [5- (2,4-diamino-pyrimidin-5-yl ethyl) -2,3-dimethoxy-phenyl] -acryloyl. -1.2, 3, 4-tetrahydro-isoquinolin-1-yl) -benzamide, mp 153-165 ° C (ethanol). 50. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1-. { 1- [4- (4-methyl-piperazin-1-ylmethyl) -phenyl] -3,4-dihydro-1H-isoquinolin-2-yl} -propenone, melting point 235-238 ° C (ethanol). 51. (E) - (RS) -3- [5- (2,4-diamino-? Irimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-imidazole-1) -yl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 155-159 ° C (acetonitrile). 52. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-imidazole-l- ylmethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 213.5-214.5 ° C (isopropanol). 53. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4- [1,2 , 4] triazol-1-yl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 156-162 ° C (ethanol / acetonitrile). 54. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4- [1, 2 , 4] triazol-1-ylmethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 190-194 ° C (acetonitrile). 55. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methylsulfanyl-phenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 220 ° C (ethanol). 56. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-yl ethyl) -2, 3-dirnetoxy-phenyl] -1- [1- (3-methanesulfonyl-phenyl) ) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 230 ° C (ethanol / acetonitrile). 57. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (6-methylsulfanyl-pyridine- 3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 165 ° C (acetonitrile). 58. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l- { 6- [( 2-hydroxy-ethyl) -methyl-amino] -pyridin-3-yl.} - 3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 156 ° C (ethanol / acetonitrile). 59. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-methyl-3,4-dihydro) -lH-isoquinolin-2-yl) -propenone, mp 136-137 ° C (ethanol / acetonitrile). 60. (E) - (RS) -3- [5- (2,4-diamino-? Irimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-hydroxymethyl-phenyl) ) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 154 ° C (ethanol). 61. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-ethyl-3,4-dihydro-lH -isoquinolin-2-yl) -propenone, mp 133 ° C (ethanol). 62. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2-methyl-4- morpholin-4-ylmethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 133-135 ° C (ethanol). 63. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- [l-methyl-5- (4-methyl-piperazin-1-ylmethyl) -lH-pyrazol-3-yl] -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point >130 ° C desc. (Ethanol / tert-butyl methyl ether). 64. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin- '5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (l-methyl-4 -morpholin-4-ylmethyl-lH-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point > 130 ° C desc. (acetonitrile). 65. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2-methyl-5- morpholin-4-ylmethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, beige foam, MS (ISP): 625.4 (M + H) +. 66. (E) - (RS) -2- [5- [2- [3- [5- (2,4-diamino-pyrimidin-5-yl-methyl) -2, 3-dimethoxyphenyl] acryloyl] -1 , 2,3,4-tetrahydroisoquinolin-1-yl] -l-methyl-lH-pyrazol-3-yl] acetamide, beige foam, MS (ISP): 583.3 (M + H) +. 67. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (l-methyl-5- morpholin-4-ylmethyl-lH-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 145.5-148 ° C (acetonitrile). 68. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- [5- (2-hydroxy ethyl) -2-methyl-2H-pyrazol-3-yl] -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, beige foam, MS (ISP): 570.3 (M + H) +. 69. (E) - (RS) - [5- [2- [3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1, 2,3,4-tetrahydro-isoquinolin-1-yl] -l-methyl-lH-pyrazol-3-yl] -acetic acid methyl ester, melting point 204-206 ° C dec. (acetonitrile). 70. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (5-hydroxymethyl-2- methyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, beige foam, MS (ISP): 556.5 (M + H) +.

EXAMPLE 71 A solution of 1.33 g of 5- (3-iodo-4,5-dimethoxy-benzyl) -pyrimidine-2,4-diamine, 1.16 g of (RS) -l- [1- (2, 5-dimethyl-2H -pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone and 0.44 g of triethylamine in 5.2 ml of N, N-dimethylformamide was treated with 0.121 g of bis (triphenyl) dichloride. phosphine) -palladium (II) and was heated at 120 ° C for 30 minutes. The mixture was then poured into 120 ml of cold sodium carbonate solution and stirred at room temperature for 10 minutes. The resulting precipitate was filtered off under suction, dried and purified on silica gel with dichloromethane / methanol 95: 5. 0.89 g (48%) of (E) - (RS) -3- [5- (2,4-diaminopyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2 , 5-dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone as a colorless solid with decomposition a > 130 ° C. MS (ISP): 540.3 (M + H) +. Analogously to the preparation of (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2 , 5-dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone described above, the following compounds were prepared: EXAMPLES 72-80 72. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-methyl- [1,2 , 3] thiadiazol-5-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (ISP): 544 (M + H) +. 73. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (1H- [1, 2, 4 ] triazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (ISP): 513.5 (M + H) +. 74. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (5-methyl-lH- imidazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 170 ° C dec. (acetonitrile). 75. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (5-pyridin-2- il-thiophen-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 162-164 ° C (dichloromethane). 76. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (5-furan-2- il-thiazol-4-yl) -3,4-dihydro-lH-Isoquinolin-2-yl] -propenone, melting point > 140 ° C, dec. (acetonitrile). 77. (E) - (RS) -1- [1- (l-Benzyl-5-methyl-lH-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, mp 207-208 ° C (ethanol). 78. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (5-methyl-2H- pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 232-233 ° C (methanol). 79. (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2-pyridin-3- il-thiazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point > 130 ° C, desc. (ethanol). 80. (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (3-dimethylamino-l- methyl-lH-pyrazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 185-188 ° C (acetonitrile).

EXAMPLE 81 273 mg of (E) - (RS) -4- [2- [3- [5- (2, 4-diamino-pyrimidin-5-yl) -2, 3-dimethoxy-phenyl] -acryloyl] - were treated. 1, 2, 3, 4-tetrahydro-isoquinolin-1-yl] -benzonitrile in 3 ml of N, N-dimethylformamide with 36 mg of sodium azide and 29 mg of ammonium chloride and stirred at 90 ° C for 30 hours. The reaction mixture was then evaporated to dryness and the residue was subjected to chromatography on MCI (25 cm x 2.5 cm 0) with the eluent water / ethanol (0-100%, v / v). The pure fractions were combined and concentrated. Recrystallization of the colorless residue in ethanol / hexane gave 74 mg of (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1 - [1- [4- (2H-tetrazol-5-yl) -phenyl] -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 208-215 ° C.

EXAMPLE 82 Analogously to example 81, from (E) - (RS) -2- [3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl ] -1,2, 3, 4-tetrahydro-isoquinoline-1-carbonitrile (Example 28) was obtained (E) - (RS) -3- [5- (2,4-diaminopyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2H-tetrazol-5-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone as a beige solid, melting point 179 ° C, desc. (ethanol). The starting materials (compounds of formula II) used in example 1-82, whose preparation has not been described, can be prepared as described above or in analogous mode.

A. Derivatives of carboxylic acid phenethylamide a) A mixture of 20 ml of ethyl pyridine-2-carboxylate and 27 ml of phenethylamine was stirred at 180 ° C for 5 hours, the ethanol formed being distilled off on a 30 cm Vigreux column. Distillation of the residue gave 30.9 g of phenethylamide of pyridine-2-carboxylic acid in the form of a yellowish oil, boiling point 150-155 ° C / 0.8 mbar. Analogously to the preparation of the phenethylamide of pyridine-2-carboxylic acid described under Aa), the following compounds were obtained: 4-methoxy-N-phenethyl-benzamide, melting point 58-59 ° C (diisopropyl ether) , (Example 8); phenazine-2-carboxylic acid phenethyl-amide, melting point 95-97 ° C (diisopropyl ether), (Example 10); Pyridine-2-carboxylic acid [2- (4-chloro-phenyl) -ethyl] -amide, melting point 85-86 ° C (diisopropyl ether), (Example 11); Pyridine-2-carboxylic acid [2- (4-methyl-phenyl) -ethyl] -amide, boiling point 165 ° C / 0.12 mbar, (Example 12); 4-chloro-pyridine-2-carboxylic acid phenethyl-amide, melting point 65 ° C (diisopropyl ether), (Example 33); 4-diethylaminomethyl-N-phenethyl-benzamide, melting point 87-88 ° C (diisopropyl ether), (Example 38); 2-amide 5- (phenethylamide) of pyridin-2, 5-dicarboxylic acid, melting point 240 ° C (ethanol), (Example 39); phenethylamide of 5-methyl-lH-imidazole-4-carboxylic acid mp 132 ° C (ethyl acetate), (Example 74). b) A solution of 10 g of 6-chloro-nicotinic acid in 80 ml of N, N-dimethylformamide and 160 ml of tetrahydrofuran was treated with 10.75 g of 1,1'-carbonyldiimidazole and stirred at room temperature for 4 hours. The reaction mixture was then treated with 8.76 g of phenethylamine and stirred at 70 ° C for a further 2 hours. The mixture was cooled to room temperature, evaporated to dryness and the residue was taken up in 200 ml of dichloromethane. The organic phase was washed three times with 50 ml of water each time, dried over sodium sulfate and evaporated to dryness. Recrystallization of the residue from isopropanol gave 11.9 g of 6-chloro-pyridine-3-carboxylic acid phenethylamide, mp 115 ° C. Analogous to the preparation of phenethylamide of 6-chloro-pyridine-3-carboxylic acid described under Ab), the following compounds were obtained: α-irimidine-5-carboxylic acid phenetylamide, melting point 95-96 ° C ( ethyl acetate / hexane), (Example 15); phenethylamide of pyrimidine-4-carboxylic acid, melting point 80-81 ° C (ethyl acetate / hexane), (Example 17); phenamyl-3-carboxylic acid phenethylamide, melting point 82-83 ° C (ethyl acetate / hexane), (Example 25); 3,6-dichloro-pyridazine-4-carboxylic acid phenethyl-amide, melting point 103-105 ° C (ethyl acetate / hexane), (Example 26); 6-hydroxy-N-phenethyl-nicotinamide, melting point 216 ° C (ethanol), (Example 30); 6-methyl-pyridine-3-carboxylic acid phenethyl-amide, mp 107 ° C (diisopropyl ether), (Example 32); 5-chloro-pyridine-2-carboxylic acid phenethyl-amide, melting point 74-76 ° C (hexane), (Example 34); 6-dimethylamino-N-phenethyl-nicotinamide, melting point 126-127 ° C (isopropanol / diisopropyl ether), (Example 35); 4-methoxy-1-oxy-pyridine-2-carboxylic acid phenethyl-amide, (Example 41); 2-amide 5- (phenethylamide) of pyridin-2, 5-dicarboxylic acid, melting point 240 ° C (ethanol), (Example 42); phenethylamide of 4-bromo-pyridine-2-carboxylic acid, mp 58-60 ° C, (Example 44); 4-morpholin-4-ylmethyl-N-phenethyl-benzamide, mp 120-121 ° C (ethyl acetate / hexane), (Example 48); 4- (4-methyl-piperazin-1-ylmethyl) -N-phenethyl-benzamide, mp 131-133 ° C (ethyl acetate / hexane), (Example 50); 4-imidazol-l-ylmethyl-N-phenethyl-benzamide, melting point 162-163 ° C (isopropanol), (Example 52); N-phenethyl-4- [1,2,4] triazol-1-ylmethyl-benzamide, mp 142.5-143.5 ° C (isopropanol / diisopropyl ether), (Example 54); 4-Methylsulfanyl-N-phenethyl-benzamide, mp 136 ° C (ethyl acetate), (Example 55); 3-methanesulfonyl-N-phenethyl-benzamide, mp 112 ° C (ethyl acetate), (Example 56); '6-Methylsulfanyl-N-phenethyl-nicotinamide, melting point 135 ° C (ethyl acetate), (Example 57); 5-pyridin-2-yl-thiophene-2-carboxylic acid phenethyl-amide, mp 131-133 ° C (ethyl acetate), (Example 75); L-benzyl-5-methyl-lH-pyrazole-3-carboxylic acid phenethyl-amide, mp 87-87.5 ° C (ethyl acetate), (Example 77); 5-methyl-2H-pyrazole-3-carboxylic acid phenethyl-amide, mp 117-117.5 ° C (ethyl acetate), (Example 78); 2-pyridin-3-yl-thiazole-4-carboxylic acid phenethyl-amide, mp 102-103 ° C, (Example 79); 3-dimethylamino-1-methyl-1H-pyrazole-4-carboxylic acid phenethyl-amide, mp 98-98.5 ° C, (Example 80). c) A solution of 1.68 g of ethyl 2, 5-dimethyl-2H-pyrazole-3-carboxylate in 3.8 ml of phenethylamine was treated with 0.10 g of rhodium (III) trichloride «trihydrate and heated to 140 ° C while It stirred for 21 hours. The mixture was then taken up in ethyl acetate / water, adjusted to pH 2-3 with 2N HCl and extracted three times with ethyl acetate. The combined organic phases were washed until neutral with saturated aqueous sodium chloride solution, dried over sodium sulfate and evaporated. Chromatographic purification on silica gel with hexane / ethyl acetate 50:50 gave 1.92 g (79%) of crystalline product of melting point 97-98 ° C. Recrystallization of a sample in tBuOMe gave 2,5-dimethyl-2H-pyrazole-3-carboxylic acid phenetyl-amide as colorless crystals of melting point 97.5-98-5 ° C. Analogously to the preparation of phenethylamide of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid described under Ac), the following compounds were obtained: 2-methyl-4-morpholin-4-phenethyl-amide IL-2-pyrazol-3-carboxylic acid, mp 90.5-91.5 ° C, (Example 62); L-methyl-5- (4-methyl-piperazin-1-ylmethyl) -lH-pyrazole-3-carboxylic acid l-methyl-5- (4-methyl-phenethyl-amide), melting point 115-116 ° C, (Example 63), l-methyl-4-morpholin-4-ylmethyl-1H-pyrazole-3-carbsylic acid phenetyl-amide, mp 106-108 ° C, (Example 64); 2-methyl-5-morpholin-4-ylmethyl-2H-pyrazole-3-carboxylic acid phenethyl-amide, melting point 113-114 ° C, (Example 65), 1H- [1, 2-phenethyl-amide] , 4] triazole-3-carboxylic acid, melting point 199-200 ° C (water), (Example 73), 5-furan-2-yl-thiazole-4-carboxylic acid phenetyl-amide, melting point 53.5- 55.5 ° C and boiling point 190-195 ° C / 0.1 mbar (bulb tube), (Example 76) d) A suspension of 9.65 g of 4-methyl- [1, 2, 3] thiadiazole-5- acid The carboxylic acid in 70 ml of dichloromethane was cooled to 5 ° C while stirring, treated with 0.15 g of 4-dimethylamino-pyridine and then with 13.8 g of N, N'-disclohexyl-carbodiimide at a ratio such that e the internal temperature < 10 ° C could be maintained. After the addition was complete, the mixture was cooled to 5 ° C and 8.92 g of phenethylamine was added at a ratio or proportion such that the internal temperature of < 37 ° C could be maintained. After the addition was complete, the mixture was stirred for a further 1 hour, then the precipitate was filtered off under suction, washed well with dichloromethane and the filtrate was evaporated. The residual yellow oil was chromatographed on silica gel with hexane / ethyl acetate 50:50. 15.66 g (92%) of phenethylamine of 4-methyl- [1,2,3] thiadiazole-5-carboxylic acid were obtained in the form of a colorless crystalline of melting point 64-68 ° C. Recrystallization of a sample in tert-butyl methyl ether gave colorless crystals of melting point 64.5-66 ° C. e) by reacting 4-methoxy-1-oxy-pyridine-2-carboxylic acid phenethylamide with phosphorus trichloride in chloroform 4-methoxy-pyridine-2-carboxylic acid phenetylamide, boiling point 160 ° was prepared C / 0.08 mbar (bulb-tube), (Example 41). f) reacting phenethylamide of 6-chloro-pyridine-3-carboxylic acid with morpholine in boiling isopropanol for 8 days gave 6-morpholin-4-yl-N-phenethyl-nicotinamide, mp 163-165 ° C (ethanol), (Example 45). By reacting phenethylamide of 6-chloro-pyridine-3-carboxylic acid with 1-methylpiperazine in boiling isopropanol, for 7 days, 6- (4-methyl-piperazin-1-yl) -N-phenethyl- hydrochloride was obtained. nicotinamide, melting point >280 ° C (acetonitrile), (Example 47). By reacting 4-fluoro-N-phenethyl-benzamide with imidazole in dimethyl sulfoxide, in the presence of potassium carbonate, for 5 days at 100 ° C, 4-imidazol-1-yl-N-phenethyl-benzamide was prepared, of fusion 160 ° C (ethyl acetate) (Example 51). Reacting 4-fluoro-N-phenethyl-benzamide with 1H- [1,2,4] triazole in dimethyl sulfoxide in the presence of potassium carbonate for 3 days at 100 ° C was prepared by N-phenethyl-4- [1, 2 , 4] triazol-1-yl-benzamide, melting point 175-176 ° C (ethyl acetate), (Example 53). g) Reacting phenethylamide of 4-bromo-pyridine-2-carboxylic acid with dimethylamine in ethanol for 18 hours, at 160 ° C 4-dimethylamino-pyridine-2-carboxylic acid phenetylamide was obtained. (Example 44). h) Reacting phenethylamide of 5-bromomethyl-2-methyl-2H-pyrazole-3-carboxylic acid (Example 66) with sodium cyanide in DMSO at 90 ° C for 20 minutes was prepared 2-methyl phenethylamide -5-cyanomethyl-2H-pyrazole-3-carboxylic acid, mp 117-118 ° C. (Example 66). i) Reacting phenethylamide of 5-bromomethyl-1-methyl-1H-pyrazole-3-carboxylic acid (E. EXAMPLE 67) with morpholine in acetone at room temperature for 2 and a half hours was prepared l-methyl phenethylamide -5-morpholin-4-ylmethyl-1H-pyrazole-3-carboxylic acid, mp 133-134 ° C. (Example 67). j) reacting l-methyl-lH-pyrazole-3,5-dicarboxylic acid 3-ethyl ester (E. EXAMPLE 70) with N, N'-carbonyldiimidazole in dichloromethane at room temperature for 2 hours, then adding phenethylamine and stirring at room temperature for a further 2 hours, ethyl l-methyl-5-phenethylcarbamoyl-lH-pyrazole-3-carboxylate was prepared, melting point 99-101 ° C. (Example 70).

B. Derivatives of 3, 4-dihydro-isoquinoline a) A mixture of 14 g of phenethylamide of pyridine-2-carboxylic acid and 300 g of polyphosphoric acid was stirred at 140 ° C for 90 minutes, at 150 ° C for 60 minutes, and finally at 155 ° C for 60 minutes. The solution was cooled to 120 ° C and poured into 2 liters of water while stirring. The mixture was stirred at room temperature for a further 15 minutes and basified (strong heating) with the addition of about 300 ml of 25% ammonium hydroxide while cooling with ice and stirring. The mixture was then extracted with 2 x 400 ml of ethyl acetate. The raspberry red organic phases were washed with 100 ml of 10% sodium chloride solution, dried over sodium sulfate, treated with about 5 g of Darco G60 and evaporated to dryness. 11.6 g of 1-pyridin-2-yl-3, 4-dihydro-isoquinoline were obtained in the form of a yellowish oil, boiling point 130 ° C / 0.08 mbar (bulb tube). Analogously to the preparation of l-pyridin-2-yl-3,4-dihydro-isoquinoline described under Ba), the following compounds were obtained: 7-methoxy-1-pyridin-2-yl-3, 4-dihydro- isoquinoline, boiling point 180 ° C / 0.07 mbar, (Example 8); l-pyrazin-2-yl-3, 4-dihydro-isoquinoline, boiling point about 135 ° C / 0.09 mbar, (Example 10); 7-chloro-l-pyridin-2-yl-3, 4-dihydro-isoquinoline, boiling point around 165 ° C / 0.06 mbar, (Example eleven); 7-methyl-l-pyridin-2-yl-3, 4-dihydro-isoquinoline, boiling point 165 ° C / 0.12 mbar, (Example 12); l-pyrimidin-5-yl-3, 4-dihydro-isoquinoline, melting point 61-63 ° C (ethyl acetate / hexane), (Example fifteen); l-pyrimidin-4-yl-3, 4-dihydro-isoquinoline, MS (El): 209M +. (Example 17); l-pyridazin-3-yl-3, 4-dihydro-isoquinoline, melting point 96-98 ° C; desc. (methylene chloride / hexane), (Example 25); 1- (3,6-dichloro-β-iridazin-4-yl) -3,4-dihydro-isoquinoline, mp 120-122 ° C (ethyl acetate / hexane), (Example 26); 5- (3, 4-dihydro-isoquinolin-1-yl) -lH-pyridin-2-one, melting point 155-156 ° C (acetonitrile), (Example 30); 1- (6-methyl-pyridin-3-yl) -3,4-dihydro-isoquinoline, melting point 68 ° C, (Example 32); 1- (4-chloro-pyridin-3-yl) -3,4-dihydro-isoquinoline, boiling point approximately 145 ° C / 0.1 mbar, (Example 33); 1- (5-chloro-pyridin-2-yl) -3,4-dihydro-isoquinoline, mp 53-54 ° C, (Example 34); [5- (3,4-dihydro-isoquinolin-1-yl) -pyridin-2-yl] -dimethylamine, boiling point 160 ° C / 0.055 mbar, (Example 35); 1- (6-chloro-pyridin-3-yl) -3,4-dihydro-isoquinoline, melting point 68 ° C (hexane), (Example 36); [4- (3, 4-dihydro-isoquinolin-1-yl) -benzyl] -diethylamine, boiling point 180 ° C / 0.2 mbar, (Example 38); 5- (3,4-dihydro-isoquinolin-1-yl) -pyridine-2-carboxamide, mp 167 ° C (ethanol) (Example 39); 1- (4-methoxy-pyridin-2-yl) -3,4-dihydro-isoquinoline, boiling point 140 ° C / 0.08 mbar (bulb-tube), (Example 41); 5- (3,4-dihydro-isoquinolin-1-yl) -pyridine-2-carboxamide, mp 167 ° C (ethanol), (Example 42); [2- (3, 4-dihydro-isoquinolin-1-yl) -pyridin-4-yl] -dimethylamine, mp 124-126 ° C (diisopropyl ether), (Example 44); 1- (6-morpholin-4-yl-pyridin-3-yl) -3,4-dihydro-isoquinoline, mp 88-89 ° C, (Example 45); 1- [6- (4-methyl-piperazin-1-yl) -pyridin-3-yl] -3,4-dihydro-isoquinoline, melting point 103-104 ° C (diisopropyl ether), (Example 47); 1- (4-morpholin-4-ylmethyl-phenyl) -3,4-dihydro-isoquinoline, melting point 122-124 ° C (hexane), (Example 48); 4- (3,4-dihydro-isoquinolin-1-yl) -benzamide, melting point 205 ° C (ethyl acetate), (Example 49); 1- [4- (4-methyl-piperazin-1-ylmethyl) -phenyl] -3,4-dihydro-isoquinoline, boiling point 185 ° C / 0.1 mbar (bulb-tube), (Example 50); 1- (4-imidazol-1-yl-phenyl) -3,4-dihydro-isoquinoline, mp 121 ° C (ethyl acetate), (Example 51); 1- (4-imidazol-1-ylmethyl-phenyl) -3,4-dihydro-isoquinoline, melting point 151-152 ° C (isopropanol / diisopropyl ether), (Example 52); 1- (4- [1, 2,4] triazol-1-yl-phenyl) -3,4-dihydro-isoquinoline, mp 161 ° C (ethanol), (Example 53); 1- (4- [1,2, 4] triazol-1-ylmethyl-phenyl) -3,4-dihydro-isoquinoline, melting point 108 ° C (isopropanol / diisopropyl ether), (Example 54); 1- (4-methylsulfanyl-phenyl) -3,4-dihydro-isoquinoline, mp 83 ° C (diisopropyl ether), (Example 55); 1- (3- (methanesulfonyl-phenyl) -3,4-dihydro-isoquinoline, mp 130 ° C (ethyl acetate), (example 56); 1- (6-methylsulfanyl-pyridin-3-yl) - 3,4-dihydro-isoquinoline, melting point 95 ° C (diisopropyl ether), (example 57); 1- (2-methyl-4-morpholin-4-ylmethyl-2H-pyrazol-3-yl) -3, 4-dihydro-isoquinoline, yellow oil, MS (TSP): 310 M +, (Example 62): 1- [1-methyl-5- (4-methyl-piperazin-1-ylmethyl) -1H-pyrazol-3-yl ] -3,4-dihydro-isoquinoline, melting point 79.5-82 ° C, (Example 63); 1- (1-methyl-4-morpholin-4-ylmethyl-1H-pyrazol-3-yl) -3, 4-dihydro-isoquinoline, brown oil, MS (ISP): 311. 2 (M + H) +, (Example 64); 1- (2-methyl-5-morpholin-4-ylmethyl-2H-pyrazol-3-yl) -3,4-dihydro-isoquinoline, brown oil, MS (El): 310 M +, (Example 65); 2- [5- (3, 4-dihydro-isoquinoline-1-yl) -1-methyl-1H-pyrazol-3-yl] -acetamide, melting point 182-185 ° C, (Examples 66 and 68); 1- (1-methyl-5-morpholin-4-ylmethyl-1H-pyrazol-3-yl) -3,4-dihydro-isoquinoline, yellow oil, MS (ISP): 311.3 (M + H) +, (Example 67); 5- (3,4-Dihydro-isoquinolin-1-yl) -1-methyl-1H-pyrazole-3-carboxylic acid, yellow foam, MS (ISP): 256. 3 (M + H) +, (Example 70); 1- (1 H- [1, 2, 4] triazol-3-yl) -3,4-dihydro-isoquinoline, melting point 165-166 ° C (ethyl acetate), (Example 73); 1- (5-methyl-lH-imidazol-4-yl) -3,4-dihydro-isoquinoline, mp 214-216 ° C, (Example 74); 1- (5-pyridin-2-yl-thiophen-2-yl) -3,4-dihydro-isoquinoline, mp 141-143 ° C (ethyl acetate), (Example 75); 1- (5-furan-2-yl-thiazol-4-yl) -3,4-dihydro-isoquinoline, mp 101-104 ° C, (Example 76); 1- (5-methyl-2H-pyrazol-3-yl) -3,4-dihydro-isoquinoline, beige foam, MS (ISP): 212.2 (M + H) +, (Example 78); 1- (3-dimethylamino-l-methyl-lH-pyrazol-4-yl) -3,4-dihydro-isoquinoline, melting point 102-103 ° C, (Example 80). b) A solution of 10.54 g of 2,5-dimethyl-2H-pyrazole-3-carboxylic acid phenethylamide in 90 ml of toluene was treated with 11.1 g of phosphorus pentachloride and the suspension was heated to reflux for 1 hour. . It was then cooled to about 50 ° C, treated with 11.1 g of anhydrous aluminum trichloride in one portion and heated to reflux for a further 3 hours. After cooling to room temperature, 90 ml of deionized water was added dropwise while cooling with ice. After vigorous stirring for 5 minutes, the organic phase was separated, washed twice with water and the combined aqueous phases were washed twice with diethyl ether. The aqueous phase was adjusted to pH >; 12 with 28% sodium hydroxide solution and extracted with ethyl acetate. Washing of the combined organic phases with saturated aqueous sodium chloride solution, drying over sodium sulfate and evaporation gave 9.01 g (92%) of a brown oil. The bulb-tube distillation of a sample gave l- (2,5-dimethyl-2H-pyrazol-3-yl) -3,4-dihydroisoquinoline as a colorless oil of boiling point 120-125 ° C / 0.2 mbar Analogously to the preparation of l- (2,5-dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-isoquinoline described under Bb), the following compounds were obtained: 1- (4-methyl- [1,2,3] thiadiazol-5-yl) -3,4-dihydro-isoquinoline, melting point 111-, 5-112 ° C (ethyl acetate), (Example 72); 1- (1-benzyl-5-methyl-1H-pyrazol-4-yl) -3,4-dihydro-isoquinoline, mp 84-84.5 ° C, (Example 77); 1- (2-pyridin-3-yl-thiazol-4-yl) -3,4-dihydro-isoquinoline, boiling point 220-230 ° C / 0.3 mbar (bulb-tube), (Example 79). c) By reacting 1- (6-chloro-pyridin-3-yl) -3,4-dihydro-isoquinoline with 2-methylaminoethanol in boiling ethanol for 3 days, 2- was prepared. { [5- (3,4-dihydro-isoquinolin-1-yl) -pyridin-2-yl] -methylamino} Ethanol, melting point 115 ° C (ethyl acetate / diisopropyl ether), (Example 58). d) By reacting 2- [5- (3, 4-dihydro-isoquinolin-1-yl) -l-methyl-lH-pyrazol-3-yl] -acetamide (B.

Examples 66 and 68) with N, N-dimethylformamide dimethyl acetal, at room temperature, for 18 hours, [5- (3,4-dihydro-isoquinolin-1-yl) -1-methyl-1H-pyrazole-3 was prepared -yl] -methyl acetate, brown oil, MS (ISP): 284.2 (M + H) + (Examples 68 and 69).

C. Derivatives of 1,2,3,4-tetrahydro-isoquinoline (compounds of formula IV) a) A solution of 6.1 g of l-pyridin-2-yl-3, 4-dihydro-isoquinoline in 220 ml of absolute ethanol was hydrogenated over 1.25 g of platinum dioxide at 20 ° C and hydrogen pressure of 1 bar during 90 minutes. After removal of the catalyst by filtration [the filtrate] was concentrated under reduced pressure. 6.71 g of (RS) -l-pyridin-2-yl-l, 2, 3, 4-tetrahydro-soquinolin in the form of a colorless cei, boiling point 140 ° C / 0.1 mbar (bulb-tube) were obtained. . A solution of 22.2 g of (RS) -l-pyridin-2-yl-1,2,3,4-tetrahydro-isoquinoline in 500 ml of hot absolute ethanol was treated with 15.85 g of D- (-) -tartaric acid. . After filtering the slightly cloudy solution, the clear solution was obtained by letting it stand at 20 ° C for 6 hours and at 5 ° C for an additional 18 hours. The formed precipitate was filtered off under suction and washed with absolute ethanol. A second crystallized was obtained immediately from the mother liquor. The precipitates were combined (15.0 g, melting point 155-158 ° C) and recrystallized from 900 ml of absolute ethanol. 11.4 g of (2S, 3S) -2, 3-dihydroxy-succinate were obtained from (R) -l-pyridin-2-yl-1,2,4,4-tetrahydro-isoquinoline (2S, 3S) -2, 3-dihydroxy-succinate (1: 1), as a colorless product, melting point 162-165 ° C. A solution of 11.16 g of (2S, 3S) -2,3-dihydroxy-succinate of (R) -l-pyridin-2-yl-1,2,3,4-tetrahydro-isoquinoline (1: 1) was dissolved in 100 ml of water and treated with 10 ml of a 25% aqueous ammonia solution. The mixture was extracted with 2 x 100 ml of diethyl ether. The combined organic phases were washed with 100 ml of water, dried over sodium sulfate [and] evaporated to dryness. The residue was distilled in a bulb-tube in order to provide 6.35 g of (R) -l-pyridin-2-yl-1,2,3,4-tetrahydroisoquinoline as a colorless oil, boiling point 135 ° C. /0.15 mbar, which crystallized with rest, melting point 50-52 ° C. Analogously to the preparation of (RS) -l-plrid? P-2-? Ll, 2, 3, 4-tetrahydro-quinoline, described under Ca), the following compounds were obtained: (RS) -l -pyridin-4-yl-l, 2,3,4-tetrahydro-i-soo ^ in li-na, punto-de-uai-on -1-24 ° C (-a -et-a-to- from -eti-lo) * (Example 6); (RS) -7-methoxy-l-pyridin-2-yl-3,4-dihydro-isoquinoline, boiling point 157 ° C / 0.07 mbar, (Example 8); (RS) -l-pyrazin-2-yl-l, 2,3,4-tetrahydro-isoquinoline, melting point 75-76 ° C (hexane), (Example 10); (R, S) -7-chloro-l-pyridin-2-yl-l, 2, 3, 4-tetrahydro-isoquinoline, boiling point 175 ° C / 0.4 mbar, (Example 11); (RS) -7-methyl-l-pyridin-2-yl-l, 2,3,4-tetrahydroiso-quinoline, boiling point 150 ° C / 0.1 mbar, (Example 12); (RS) -l-pyrimidin-5-yl-l, 2, 3, 4-tetrahydro-isoquinoline, mp 75-77 ° C (methylene chloride / cyclohexane), (Example 15); (RS) -l-pyrimidin-4-yl-l, 2,3,4-tetrahydro-isoquinoline hydrochloride (1: 1.7), melting point 150 ° C, dec. (ethanol), (Example 17); (RS) -l-pyridazin-3-yl-l, 2,3,4-tetrahydro-isoquinoline, mp 76-78 ° C (dichloromethane / hexane), (Example 25); (RS) -l-pyridazin-4-yl-l, 2,3,4-tetrahydro-isoquinoline hydrochloride (1: 1.7), mp 115 ° C, dec * (ethanol), (Example 26); (RS) -1- (6-Methyl-pyridin-3-yl) -1, 2, 3, 4-tetrahydro-isoquinoline, mp 82 ° C (hexane), (Example 32); (RS) -dimethyl- [5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -pyridin-2-yl] -amine, mp 94-95 ° C (diisopropyl ether), ( Example 35); (RS) -diethyl- [4- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -benzyl] -amine, boiling point 160 ° C / 0.055 mbar, (Example 38); (R, S) -5- (1, 2,3,4-tetrahydro-isoquinolin-1-yl) -pyridinecarboxamide, melting point 200 ° C (isopropanol), (Example 39); (R, S) -l- (4-methanesulfonyl-phenyl) -1,2, 3,4-tetrahydro-isoquinoline, mp 118-120 ° C (diisopropyl ether), (Example 40); (RS) -1- (4-methoxy-pyridin-2-yl) -1,2,3,4-tetrahydro-isoquinoline, boiling point 130 ° C / 0.05 mbar, (Example 41); (RS) -5- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -pyridine-2-carboxamide, melting point 200 ° C (isopropanol), (Example 42); (RS) -dimethyl- [2- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -pyridin-4-yl] -amine, mp 106-109 ° C (diisopropyl ether), ( Example 44); (RS) -1- (6-morpholin-4-yl-pyridin-3-yl) -1, 2, 3, 4-tetrahydro-isoquinoline, melting point 151-152 ° C (isopropanol), (Example 45); (RS) -1- [6- (4-Methyl-piperazin-1-yl) -pyridin-3-yl] -1,2,3,4-tetrahydro-isoquinoline, mp 132.5-133.5 ° C (ether) diisopropyl), (Example 47); (RS) -l- (4-morpholin-4-ylmethyl-phenyl) -1,2,3,4-tetrahydro-isoquinoline, melting point 128-129 ° C (hexane), (Example 48); (RS) -4- (1, 2,3,4-tetrahydro-isoquinolin-1-yl) -benzamide, mp 208 ° C (ethanol), (Example 49); (RS) -1- [4- (4-Methyl-piperazin-1-ylmethyl) -phenyl] -1,2,3,4-tretrahydro-isoquinoline, melting point 96-98 ° C (hexane), (Example fifty); (RS) -1- (4-imidazol-1-yl-phenyl) -1,2,3,4-tetrahydro-isoquinoline, mp 125 ° C (ethyl acetate), (Example 51); (RS) -l- (4-imidazol-l-ylmethyl-phenyl) -1,2, 3,4-tetrahydro-isoquinoline, melting point 102-104 ° C (t-BuOMe), (Example 52); (RS) -l- (4- [1,2,4] triazol-l-yl-phenyl) -1,2, 3,4-tetrahydro-isoquinoline, mp 133 ° C (ethyl acetate / diisopropyl ether ), (Example 53); (RS) -1- (L-methyl-4-morpholin-4-ylmethyl-lH-pyrazol-3-yl) -1,2,4,4-tetrahydro-isoquinoline, yellowish eite, MS (ISP): 313 , 2 (M + H) +, (Example 64); (RS) -1- (2-methyl-5-morpholin-4-ylmethyl-2H-pyrazol-3-yl) -1,2, 3,4-tetrahydro-isoquinoline, yellowish oil, MS (ISP): 313.2 ( M + H) +, (Example 65); (RS) -2- [l-Methyl-5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -lH-pyrazol-3-yl] -acetamide, melting point 145-146 ° C , (ethyl acetate / diethyl ether), (Example 66); (RS) -1- (1-methyl-5-morpholin-4-ylmethyl-1H-pyrazol-3-yl) -1,2,3,4-tetrahydro-isoquinoline, yellowish oil, MS (ISP): 313.3 ( M + H> +, (Example 67); (RS) - [1-methyl-5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -lH-pyrazol-3-yl] - methyl acetate, yellow oil, MS (El): 285 M +, (Example 69) b) A solution of 3.48 g of 4- (3,4-dihydro-isoquinolin-1-yl) -benzonitrile in 90 ml of methanol it was cooled to 5 ° C while stirring and treated with 1.7 g of sodium borohydride within 30 minutes. After the addition was complete, the mixture was stirred at 5 ° C for an additional 30 minutes. Then 50 ml of water was slowly added dropwise and the mixture was stirred at room temperature for a further 10 minutes. The mixture was diluted with water and extracted three times with ethyl acetate. The combined organic phases were dried over sodium sulfate and evaporated. 3.15 g of crystalline (RS) -4- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -benzonitrile were obtained. Recrystallization of a sample in diisopropyl ether gave colorless crystals of melting point 94-97 ° C.

Analogously to the preparation of (RS) -4- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -benzonitrile described under Cb), the following compounds were obtained: (RS) -5- ( 1,2,3,4-tetrahydro-isoquinolin-1-yl) -1H-pyridin-2-one, mp 114-115 ° C (acetonitrile), (Example 30); (RS) -1- (4-Chloro-pyridin-2-yl) -1,2,4,4-tetrahydro-isoquinoline, boiling point approximately 140 ° C / 0.1 mbar (Example 33); (RS) -1- (5-Chloro-pyridin-2-yl) -1,2,3,4-tetrahydro-isoquinoline, mp 92-93 ° C (hexane), (Example 34); (RS) -l- (6-Chloro-pyridin-3-yl) -l, 2, 3, 4-tetrahydro-isoquinoline, melting point 103 ° C (hexane),. { Example 36); (RS) -l- (4- [1,2,4] triazol-l-ylmethyl-phenyl) -1,2, 3,4-tetrahydro-isoquinoline, melting point 96-98 ° C (ethyl acetate / hexane), (Example 54); (RS) -1- (4-Methylsulfanyl-phenyl) -1,2,3,4-tetrahydro-isoquinoline, melting point 94 ° C (diisopropyl ether), (Example 55); (RS) -1- (3-methanesulfonyl-p-phenyl) -1,2,3,4-tetrahydro-isoquinoline, boiling point 250 ° C / 0.15 mbar (bulb-tube), (Example 56); (RS) -l- (6-methylsulfanyl-pyridin-3-yl) -l, 2,3,4-tetrahydro-isoquinoline, melting point 86 ° C (isopropanol), (Example 57); (RS) -2-. { methyl- [5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -pyridin-2-yl] -amino} Ethanol, MS (El): 283 M +, (Example 58). c) A solution of 9.08 g of 1- (2, 5-dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-isoquinoline in 400 ml of absolute methanol was treated at room temperature with a spatula tip of bromocresol green as well as 2.79 g of sodium cyanoborohydride. Throughout the reaction period a pH of 4-6 was maintained by the addition of HCl gas dissolved in absolute methanol (approximately 2N). After 2.5 hours the solvent was distilled off on a rotary evaporatorThe residue was taken up in ethyl acetate and washed with semi-saturated sodium bicarbonate solution. Re-extraction of the aqueous phase with ethyl acetate, washing of the combined organic phases with saturated sodium chloride solution, aqueous, drying over sodium sulfate and evaporation gave 9.22 g of a brown oil which was purified on silica gel with acetate ethyl / methanol 75:25. 7.44 g (81%) of (RS) -1- (2,5-dimethyl-2H-pyrazol-3-yl) -l, 2f 3, 4-tetra-hydro-isoquinol -na like an amaxi-1-lo oil. MS (El): 227 M +.

Analogously to the preparation of (RS) -l- (2,5-dimethyl-2H-pyrazol-3-yl) -1,2,3,4-tetrahydro-isoquinoline described under Ce), the following compounds were obtained : (RS) -1- (2-methyl-4-morpholin-4-ylmethyl-2H-pyrazol-3-yl) -1, 2, 3, 4-tetrahydro-isoquinoline, colorless oil, MS (TSP): 312 M +, (Example 62); (RS) -1- [l-Methyl-5- (4-methyl-piperazin-1-ylmethyl) -1H-pyrazol-3-yl] -1,2,3,4-tetrahydro-isoquinoline, yellowish oil, dot boiling 190-195 ° C / 0.15 mbar (bulb-tube), (Example 63); (RS) -l- (4-methyl- [1,2,3] thiadiazol-5-yl) -1,2, 3,4-tetrahydro-isoquinoline, melting point 85-86 ° C (digestion in pentane) , (Example 72); (RS) -1- (1 H- [1,2,4] triazol-3-yl) -1,2, 3,4-tetrahydro-isoquinoline, melting point 172-173 ° C (isopropanol), (Example, 73); (RS) -l- (5-Methyl-lH-imidazol-4-yl) -l, 2,3,4-tetrahydro-isoquinoline, mp 179-180 ° C (isopropanol), (Example 74); (RS) -1- (5-pyridin-2-yl-thiophen-2-yl) -1, 2, 3, 4-tetrahydro-isoquinoline, melting point 111-112 ° C (tert-butyl methyl ether) , (Example 75); (RS) -l- (5-furan-2-yl-thiazol-4-yl) -l, 2,3,4-tetrahydro-isoquinoline, dark red resin, MS (El): 282 M +, (Example 76); (RS) -1- (1-Benzyl-5-methyl-1H-pyrazol-3-yl) -1,2,4,4-tetrahydro-isoquinoline, colorless oil, MS (ISP): 304.3 (M + H) +, (Example 77); (RS) -1- (5-methyl-2H-pyrazol-3-yl) -1,2,3,4-tetrahydroisoquinoline, beige foam, MS (El): 213 M +, (Example 78); (RS) -1- (2-pyridin-3-yl-thiazol-4-yl) -1,2,3,4-tetrahydroisoquinoline, yellowish oil, MS (El): 293 M +, (Example 79); (RS) -dimethyl- [l-methyl-4- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -lH-pyrazol-3-yl) -amine, yellow oil, MS (ISP): 257.5 (M + H) +, (Example 80). d) Prepared. (RS) - [4- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -phenyl] -methanol, melting point 138 ° C (ethanol), reducing ethyl 4- (1, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -benzoate with lithium aluminum hydride in tetrahydrofuran at 0 ° C (Example 60). (RS) -2- [1-methyl-5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -lH-pyrazol-3-yl] -ethanol yellowish oil, MS (ISP): 258.3 (M + H) + (Example 68); (RS) - [1-methyl-5- (1,2,3,4-tetrahydro-isoquinolin-1-yl) -lH-pyrazol-3-yl] -methanol, yellow foam, MS (ISP): 244.2 ( M + H) +, (Example 70).

D. Derivatives of 1- (3, 4-dihydro-lH-isoquinolin-2-yl) -propenone (compounds of formula III) A solution of 2.44 ml of acryloyl chloride in 5 ml of toluene was added dropwise, while stirring and cooled with ice within 15 minutes to 6.2 g of (R) -l-pyridin-2-yl-2, 3,4-tetrahydro-isoquinoline and 5 ml of triethylamine in 80 ml of toluene. After stirring at room temperature, the mixture was treated for a further 10 minutes with 100 ml of water and extracted with 2 x 80 ml of diethyl ether. The combined organic phases were washed with 50 ml of water, dried over sodium sulfate and evaporated to dryness. 8.07 g of (R) -l- (l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone were obtained as a viscous resin, boiling point 180 ° C / 0.1 mbar . Analogous to the preparation of (R) -l- (l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone described under D., the following compounds were obtained: - (3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 160 ° C / 1.5 mbar, (Example 2); (RS) -1- (l-pyridin-2-yl-3,4-dihydro-lH-soquinolin-2-yl) -propenyone, boiling point about 180 ° C / 0.8 mbar, (Example 3); 1- (7-chloro-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point about 170 ° C / 0.1 mbar, (Example 4); (RS) -l- (l-phenyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point approximately 175 ° C / 0.1 mbar, (Example 5); (RS) -1- (l-pyridin-4-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 250 ° C / 0.2 mbar, (Example 6); (RS) -1- (l-pyridin-3-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, mp 83 ° C (diisopropyl ether), (Example 7); (RS) -1- (7-methoxy-l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 240 ° C / 0.12 mbar, (Example 8); (RS) -1- (L-pyrazin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, melting point 95-97 ° C (toluene / hexane), (Example 10); (RS) -l- (7-chloro-l-pyridin-2-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 220 ° C / 0.06 mbar, (Example 11); (RS) -1- (7-Methyl-l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 190 ° C / 0.05 mbar, (Example 12); (RS) -l- [l- (4-Chloro-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point 190 ° C / 0.2 mbar, (Example 13); (RS) -1- (L-cyclohexyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 250 ° C / 0.15 mbar, (Example 14); (RS) -l- (l-pyrimidin-5-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, MS (El): 265 M +, (Example 15); (RS) -l- [1- (4-Methyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point 190 ° C / 0.2 mbar, (Example 16); (RS) -l- (l-pyrimidin-4-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, MS (ISP): 266.4 (M + H) +, (Example 17); (RS) -l- (l-Benzyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, oil, (Example 18); (RS) -1- (l-Isobutyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 200 ° C / 0.3 mbar, (Example 19); (RS) -1- [1- (4-methoxy-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point approximately 200 ° C / 0.08 mbar, (Example 20); (RS) -1- (L-cyclopropyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, boiling point 200 ° C / 0.3 mbar, (Example 22); (RS) -4- (2-acryloyl-1,2,3,4-tetrahydro-isoquinolin-1-yl) -benzonitrile, boiling point 220 ° C / 0.1 mbar, (Example 23); (RS) -1- [1- (4-dimethylamino-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point about 180 ° C / 0.08 mbar, (Example 24); (RS) -1- (L-pyridazin-3-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, MS (El): 265 M +, (Example 25); (RS) -1- (L-pyridazin-4-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, MS (El): 265 M +, (Example 26); (RS) -1- (L-thiophen-2-yl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, mp 110 ° C (diisopropyl ether), (Example 27); (RS) -2-acryloyl-1,2,4,4-tetrahydro-isoquinoline-1-carbonitrile, mp 101-104 ° C (ethanol), (Example 28); (RS) -1- [1- (4-trifluoromethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point 180 ° C / 0.07 mbar, (Example 29); (RS) -1- [1- (6-hydroxy-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, oil, (Example 30); (RS) -4- (Ethyl 2-acryloyl-l, 2,3,4-tetrahydro-isoquinolin-1-yl) -benzoate, boiling point about 220 ° C / 0.1 mbar, (Example 31); (RS) -1- [1- (6-Methyl-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, oil, MS (ISP): 279.4 (M + H ) +, (Example 32); (RS) -l- [l- (6-chloro-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, oil, MS (El): 298 M +, (EXAMPLE 36); (RS) -1- [1- (4-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point approximately 180 ° C / 0.1 mbar, ( Example 33); (RS) -1- [1- (5-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, boiling point approximately 195 ° C / 0.065 mbar, ( Example 34); (RS) -1- [1- (6-Dimethylamino-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 125-126 ° C (hexane), (Example 35); (RS) -1- [1- (4-diethylaminomethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, oil, (Example 38); (R, S) -5- (2-acryloyl-1,2,4,4-tetrahydro-so-quinolin-1-yl) -pyridine-2-carboxamide, MS (ISP): 308.3 (M + H) +, ( Example 39); 1- [1- (4-methanesulfonyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, resin, (Example 40); (RS) -1- [1- (2, 5-Dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 125-126.5 ° C , (Example 41); 7 (RS) -l- [l- (4-Methyl- [1,2,3] thiadiazol-5-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 136- 137 ° C, (Example 42); (RS) -1- (1 H- [1, 2, 4] triazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless foam, MS (ISP): 255.4 ( M + H) +, (Example 43); (RS) -1- [1- (5-Methyl-lH-imidazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 159-160 ° C (acetate) ethyl), (Example 44); (RS) -1- [1- (5-? Iridin-2-yl-thiophen-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, yellow foam, MS (El) : 346 M +, (Example 45); (RS) -1- [1- (5-furan-2-yl-thiazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, red resin, MS (El): 336 M +, (Example 46); (RS) -1- [1- (l-Benzyl-5-methyl-lH-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless oil, MS (El ): 357 M +, (Example 47); (RS) -1- [1- (5-Methyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless foam, MS (El): 267 M + , (Example 48); (RS) -! - [! - (2-pyridin-3-yl-thiazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 111.5-114 ° C (ethyl acetate / pentane 1: 1), (Example 49); (RS) -1- [1- (3-dimethylamino-l-methyl-lH-pyrazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 93-95 ° C (tert-butyl methyl ether / pentane 1: 1), (Example 50); (RS) -1- [1- (4-imidazol-l-yl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 51); (RS) -1- [1- (4-imidazol-l-ylmethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 52); (RS) -1- [1- (4- [1, 2,4] triazol-1-yl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (Example 53); (RS) -1- [1- (4- [1,2, 4] triazol-1-ylmethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (ISP): 345.2 (M + H) +, (Example 54); (RS) -1- [1- (4-Methylsulfanyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (El): 309 M +, (Example 55); (RS) -1- [1- (3-methanesulfonyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (El): 341 M +, (Example 56); (RS) -1- [1- (€ -methylsulfanyl-pyridin-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (ISP): 311.2 (M + H) + , (Example 57); (RS) -1- [l-. { 6- [(2-hydroxy-ethyl) -methyl-amino] -pyridin-3-yl} -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (ISP): 338.2 (M + H) +, (Example 58); (RS) -1- (L-methyl-3,4-dihydro-lH-isoquinolin-2-yl) -propenone, MS (El): 201 M +, (Example 59); (RS) -1- [1- (4-hydroxymethyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, MS (El): 293 M +, (Example 60); (RS) -1- (1-ethyl-3, 4-dihydro-1H-isoquinolin-2-yl) -propenone, boiling point 150 ° C / 043 mbar (bulb-tube), (Example 61); (RS) -1- [1- (2-methyl-4-morpholin-4-ylmethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, point fusion 127.5-130 ° C, (Example 62); (RS) -1- [1- [1-methyl-5- (4-methyl-piperazin-1-ylmethyl) -lH-pyrazol-3-yl] -3,4-dihydro-1H-isoquinolin-2-yl ] -propenone, oil, MS (ISP): 380.4 (M + H) +, (Example 63); (RS) -1- [1- (2, 5-Dimethyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 125-126.5 ° C , (Example 71); (RS) -! - [! - (4-methyl- [1,2,3] thiadiazol-5-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 136- 137 ° C, (Example 72); (RS) -1- (1 H- [1, 2, 4] triazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless foam, MS (ISP): 255.4 ( M + H) +, (Example 73); (RS) -1- [1- (5-Methyl-lH-imidazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 159-160 ° C (acetate) ethyl), (Example 74); (RS) -1- [1- (5-pyridin-2-yl-phen-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, yellow foam, MS (E): 346 M +, (Example 75); (RS) -1- [1- (5-furan-2-yl-thiazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, red resin, MS (El): 336 M +, (Example 76); (RS) -1- [1- (l-Benzyl-5-methyl-lH-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless oil, MS (El ): 357 M +, (Example 77); (RS) -1- [1- (5-Methyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, colorless foam, MS (El): 267 M + , (Example 78); (RS) -1- [1- (2-pyridin-3-yl-thiazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, melting point 111.5-114 ° C (ethyl acetate / pentane 1: 1), (Example 79); (RS) -1- [1- (3-dimethylamino-l-methyl-lH-pyrazol-4-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, mp 93-95 ° C (tert-butyl methyl ether / pentane 1: 1), (Example 80). The following compounds were obtained by reaction with acryloyl chloride in dichloromethane at < -50 ° C: (RS) -1- [1- (1-methyl-4-morpholin-4-ylmethyl-1H-pyrazol-3-yl) -3,4-dihydro-1H-isoquinolin-2-yl] -propenone, melting point > 106 ° C desc. 7 (tert-butyl methyl ether), (Example 64); (RS) -1- [1- (2-Methyl-5-morpholin-4-ylmethi-2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, point melting 162-165 ° C (tert-butyl methyl ether); (Example 65); (RS) -2- [S- (2-acryloyl-1,2,4,4-tetrahydro-isoquinolin-1-yl) -l-methyl-lH-pyrazol-3-yl] -acetamide, melting point 168 -170 ° C, (Example 66); (RS) -l- [l- (l-methyl-5-morpholin-4-ylmethyl-lH-pyrazolo-3-yl) -3,4-dihydro-lH-isoquininoin-2-yl] -propenone, yellow oil , MS (ISP): 367.3 (M + H) +, (Example 67); (RSJ-1- [1- [5H2-hydroxy-ethyl) '- 2-methyl-2H-pyrazol-3-yl] -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, point mp 133-134 ° C (acetonitrile), (Example 68); (RS) - [5- (2-acryloyl-l, 2, 3, 4-tetrahydro-isoquinolin-1-yl) -l-methyl-1H-pyrazol-3-yl] -acetic acid methyl ester, melting point 128 -129! > C (ethyl acetate), (Example 69); (RS) -l- [1- (5-Hydroxymethyl-2-methyl-2H-pyrazol-3-yl) -3,4-dihydro-lH-iso-quinolin-2-yl] -propenone, melting point -136 ° C (digestion in pentane), (Example 70).

AND_. Derivatives of 1- (3, 4-dihydro-lH-isoquinolin-2-yl) -propinone (compounds of formula III; Q = ethynylene) (i) A solution of 1.47 g of bis (trichloromethyl) carbonate in 10 ml of methylene chloride was added dropwise within 20 minutes to a solution of 2 g of 1, 2, 3, 4-tetrahydro-isoquinoline in 30 ml of methylene chloride and 2.5 ml of triethylamine under argon at 0 ° C. The reaction mixture was stirred at room temperature for 2 hours, then diluted with 50 ml of methylene chloride and washed with 50 ml of water, 50 ml of a 5% hydrochloric acid solution, 50 ml of a saturated solution. of sodium hydrogen carbonate and 50 ml of a saturated solution of sodium chloride. The organic phases were dried over magnesium sulfate, concentrated, and the residue was dried at room temperature and at about 12 mbar. 2.74 g (94%) of 3,4-dihydro-lH-isoquinoline-2-carbonyl chloride was obtained as a pale orange oil, MS (El): 195 M +. (ii) A solution of 2.73 g of 3,4-dihydro-lH-isoquinoline-2-carbonyl chloride, 55 mg of 4-dimethylamino-pyridine, 1.36 g of N, 0-dimethylhydroxylamine hydrochloride and 4.85 ml of tri-ethylamine in 30 ml of methylene chloride was heated to boiling under reflux for 22 hours. The reaction mixture was treated at room temperature with 50 ml of a 5% sodium carbonate solution and extracted twice with 50 ml of methylene chloride each time. The combined organic phases were washed once with 50 ml of water and once with 50 ml of a saturated solution of sodium chloride, dried over magnesium sulfate and concentrated. The residue was triturated with 50 ml of methyl t-butyl ether, a small amount of insoluble residue was filtered off under suction and the filtrate was concentrated. The residue was dried at room temperature and at about 12 mbar. 2.87 g (93%) of 3,4-dihydro-lH-isoquinoline-2-carboxylic acid methoxymethylamide was obtained in the form of an orange oil. MS (El): 220 M +. (iii) 9.08 ml of a 0.5 molar solution of ethynylmagnesium bromide in tetrahydrofuran was added dropwise within 20 minutes to a solution of 1 g of 3,4-dihydro-lH-isoquinoline-2-methoxy-methyl-amide. carboxylic acid in 5 ml of tetrahydrofuran under argon at 0 ° C. The reaction mixture was stirred at 0 ° C for 1 hour and at room temperature for 1 hour. The orange solution was poured into 50 ml of a saturated solution of ammonium chloride and extracted twice with 50 ml of ethyl acetate each time. The combined organic phases were washed twice with 50 ml of water each time, once with 50 ml of saturated sodium chloride solution, dried over magnesium sulfate and concentrated. 0.48 g (57%) of l- (3,4-dihydro-lH-isoquinolin-2-yl) -propenone was obtained in the form of a yellowish oil. MS (El): 185 M +.

F. Preparation of the phenethylamide derivatives of the carboxylic acid used in A.

Educt for Example 62 i) Ethyl 4-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylate, colorless oil, MS was prepared (TSP): 184 M +, reacting ethyl 4-hydroxymethyl-lH-pyrazole-3-carboxylate, melting point 119-121 ° C, with methyl iodide and potassium carbonate in acetone at room temperature for 2 hours. (ii) Ethyl 4-bromomethyl-2-methyl-2H-pyrazole-3-carboxylate, colorless oil, MS (TSP): 246 and 248 M + was prepared by reacting 4-hydroxymethyl-2-methyl-2H-pyrazole- Ethyl 3-carboxylate with tetrabromomethane and triphenylphosphine in diethyl ether at room temperature for 22 hours. (iii) Ethyl 2-methyl-4-morpholin-4-ylmethyl-2H-pyrazole-3-carboxylate was prepared, semi-crystalline, colorless product, MS (TSP): 253 M + f by reacting 4-bromomethyl-2 ethyl-2-methyl-2-pyrazole-3-carboxylate with morpholine in acetone at room temperature for 1.5 hours. Similarly, the following compounds were prepared: Duct for example 63 i) Prepared ethyl 5-hydroxymethyl-l-methyl-lH-pyrazole-3-carboxylate, colorless oil; boiling point 140-145 ° C / 0.18 mbar (bulb / tube), reacting ethyl 5-hydroxymethyl-1H-pyrazole-3-carboxylate, melting point 92-93 ° C, with methyl iodide and potassium carbonate in Acetone at room temperature for 2 hours. (ii) Ethyl 5-broth-otnetyl-l-methyl-lH-pyrazole-3-carboxylate, melting point 68.5-69.5 ° C, was prepared by reacting 5-hydroxymethyl-1-methyl-1H-pyrazole-3. ethyl carboxylate with tetrabromomethane and triphenylphosphine in diethyl ether at room temperature for 17 hours. (iii) Ethyl l-methyl-5- (4-methyl-piperazin-1-ylmethyl) -l-pyrazole-3-sarboxylate, yellow oil, EM (El): 266 M + was prepared by reacting 5-bromomethyl- ethyl l-methyl-lH-pyrazole-3-carboxylate with 1-methylpiperazine in acetone at room temperature for 3 hours.

Educt for example 64 i) Ethyl 4-hydroxymethyl-l-methyl-lH-pyrazole-3-carboxylate, melting point 73-75 ° C, was prepared by reacting 4-hydroxymethyl-1H-pyrazole-3-carboxylate of ethyl, melting point 119-121 ° C, with methyl iodide and potassium carbonate in acetone at room temperature for 2 hours. (ii) Ethyl 4-bromomethyl-l-methyl-lH-pyrazole-3-carboxylate, mp 112-114 ° C, was prepared by reacting 4-hydroxymethyl-1-methyl-1H-pyrazole-3-carboxylate of ethyl with tetrabromomethane and triphenylphosphine and a mixture of diethyl ether / onoglyme at room temperature for 4 days, (iii) ethyl l-methyl-4-morpholin-4-ylmethyl-lH-pyrazole-3-carhoxylate, yellowish oil, MS (ISP): 254.3 (M + H) +, reacting ethyl 4-bromomethyl-l-methyl-lH-pyrazole-3-carboxylate with morpholine in acetone at room temperature for 30 minutes.

Educto for example 65 i) Prepared 5-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylate ethyl ester, colorless oil, - boiling point 1QQ-1Q5 ° C / Q.15 mbar (bulb-tube) reacting Ethyl 5-hydroxymethyl-lH-pyrazole-3-carboxylate, melting point 92-93 ° C, with methyl iodide and potassium carbonate in acetone at room temperature for 2 hours. ii) Ethyl 5-bromomethyl-2-methyl-2H-pyrazole-3-carboxylate, melting point 69-71 ° C, was prepared by reacting ethyl 5-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylate with tetrabromoethane and triphenylphosphine in diethyl ether at room temperature for 28 hours. iii) Ethyl 2-methyl-5-morpholin-4-ylmethyl-2H-pyrazole-3-carboxylate, brown oil, MS (TSP): 253 M + was prepared by reacting 5-bromometii-2-methyl-2H-pyrazole Ethyl 3-carboxylate with morpholine in acetone at room temperature for 1 hour.

Educts for Examples 66 and 67 i) A mixture of ethyl 5-methoxymethyl-l-methyl-lH-pyrazole-3-carboxylate and ethyl 5-methoxymethyl-2-methyl-2H-pyrazole-3-carboxylate was obtained, yellow oil, MS (El): 198.1 M +, methylating a mixture of ethyl 5-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylate and ethyl 5-hydroxymethyl-l-methyl-lH-pyrazole-3-carboxylate with NaH and methyl iodide in DMF. ii) analogously to Ac) from a mixture of ethyl 5-methoxymethyl-l-methyl-lH-pyrazole-3-carboxylate and ethyl 5-methoxymethyl-2-methyl-2H-pyrazole-3-carboxylate, a 1: 1 mixture of 5-hydroxymethyl-1-methyl-1H-pyrazole-3-carboxylic acid phenetylamide and 5-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylic acid phenetylamide was prepared, yellow oil, MS (El): 259.1 M +. Chromatographic separation on silica gel gave not only the desired product, but also phenethylamide of isomeric 5-bromomethyl-1-methyl-1H-pyrazole-3-carboxylic acid, yellow oil, MS (El): 321 and 323 M +. iii) 5-Bromomethyl-2-methyl-2H-pyrazole-3-carboxylic acid phenetyl-amide was obtained, melting point 112-113 ° C by reacting a 1: 1 mixture of 5-hydroxymethyl-5-hydroxymethylphenethylamide l-methyl-lH-pyrazole-3-carboxylic acid and 5-hydroxymethyl-2-methyl-2H-pyrazole-3-carboxylic acid phenethylamide with tetrabromomethane and triphenylphosphine in ethyl acetate at room temperature for 21 hours and then separating the obtained mixture by chromatography.

Educte of Example 70 Ethyl 1-methyl-1H-pyrazole-3,5-dicarboxylic acid 3-ethyl ester, melting point 128-129 ° C was prepared by oxidizing 5-hydroxymethyl-1-methyl-1H-pyrazole-3. ethyl carboxylate with sodium periodate and a catalytic amount of ruthenium trichloride in a mixture of CCl4 / MeCN / H20 at 20-40 ° C for 1 1/2 hours. In a manner known per se, pharmaceutical preparations can be produced according to the following formulations: EXAMPLE A Tablets or tablets: Sulfamethoxazole 400 mg Compound of the formula I, for example (E) - (R) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxyphenyl] -1- (l-pyridine-2 -yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone 80 mg PRIMOJEL (starch derivative) 6 mg POVIDONE K30 (polyvinylpyrrolidone) 8 mg Magnesium stearate 6 mg Total weight 500 mg EXAMPLE B Tablets or Tablets: Compound of formula I, for example (E) - (R) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1 - (l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone 100 mg Corn starch 15 mg Talc 3 mg Magnesium stearate 2 mg 120 mg EXAMPLE C Injection solutions: Compound of formula I, for example (E) - (R) -3- [5- (2,4-diaminopyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- (l- pyridin-2-yl-3, 4-dihi-dro-lH-isoquinolin-2-yl) -propenone 5 mg Glycofurol 75 0.2 ml Sterile double-distilled water up to 1.0 ml EXAMPLE D Injection solutions Compound of formula I, for example (E) - (R) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxyphenyl] -1- (l-pyridine -2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone 5 mg • Propylene glycol 0.5 ml Sterile double-distilled water up to 1.0 ml It is noted that in relation to this date, the best method known by the applicant to carry out the aforementioned invention, is that which is clear from the present description of the invention. Having described the invention as above, the content of the following is claimed as property

Claims (15)

1. Compounds of the general formula characterized in that R1 signifies lower alkoxy, R2 signifies lower alkoxy bromo or hydroxy, R3 signifies hydrogen, lower alkyl, cycloalkyl, aryl, heteroaryl, arachidyl, heteroaralkyl or cyano, R4 and R5 signify each, independently, hydrogen, lower alkyl, lower alkoxy , halogen, hydroxy, amino, di (lower alkyl) -amino, cyano or nitro and Q means ethynylene or vinylene, as well as their pharmaceutically usable salts.
2. 2. Compounds of formula I, according to claim 1, characterized in that R1 and R2 mean lower alkoxy, especially methoxy; R3 means substituted phenyl, or pyridyl, especially 2- or 3-pyridyl, or substituted pyridyl, or thienyl; R4 means hydrogen; and R5 means hydrogen or lower alkoxy, especially methoxy.
3. 3. Compounds of the formula I, according to claim 1 or 2, characterized in that Q is vinylene.
4. 4. The compound (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (2, 5-dimethyl- 2H-pyrazol-3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone.
5. 5. Compound (E) - (RS) -1- (1-cyclopropyl-3,4-dihydro-1H-isoquinolin-2-yl) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone.
6. 6. The compound (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (6-methyl-pyridine- 3-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone.
7. 7. The compound (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-dimethylaminopyridin-2- il) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone.
8. 8. The compound (E) - (RS) -4- (2- { 3- [5- (2,4-diaminopyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1 , 2,3,4-tetrahydro-isoquinolin-1-yl) -benzamide.
9. .9. Compound (E) - (RS) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- [1- (4-ethylsulfanylphenyl) -3 , 4-dihydro-lH-isoquinolin-2-yl] -propenone.
10. 10. The compounds (E) - (R) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -1- (l-pyridin-2-yl-3 , 4-dihydro-lH-isoquinolin-2-yl) -propenone, (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl ] -1- (1-pyridin-2-yl-3, 4-dihydro-1H-isoquinolin-2-yl) -propenone, (E) - (RS) -3- [5- (2, 4-diamino- pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- (7-methoxy-l-pyridin-2-yl-3, 4-dihydro-lH-isoquinolin-2-yl) -propenone, (E ) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -1- [1- (4-methyl-phenyl) -3,4 -dihydro-iH-isoquinolin-2-yl] -propenone, (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] - 1- [1- (4-hydroxy-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone, (E) - (RS) -4- [2- [3- [5- < 2,4-diamino-pyrimidin-5-yl) -2,3-dimethoxy-phenyl] -acryloyl] -1,2,3,4-tetrahydro-isoquinolin-1-yl] -benzonitrile, (E) - (RS ) -3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2,3-dimethoxy-phenyl] -l- (l-thiophen-2-yl-3,4-dihydro-lH-isoquinoline) -2-yl) -propenone, (E) - (RS) -1- [1- (5-chloro-pyridin-2-yl) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, (E) - (RS) -1- [1- (6-chloro-pyridin-3- il) -3,4-dihydro-lH-isoquinolin-2-yl] -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -propenone, (E ) - (RS) -5- [2- [3- [5- (2,4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl] -acryloyl] -1, 2,3,4 -tetrahydro = isoquinolin-1-yl] -pyridine-2-carboxamide, (E) - (RS) -3- [5- (2, 4-diamino-pyrimidin-5-ylmethyl) -2, 3-dimethoxy-phenyl ] -1- [1- (4-methanesulfonyl-phenyl) -3,4-dihydro-lH-isoquinolin-2-yl] -propenone.
11. 11. Compounds according to any of claims 1-10 for use as medicaments.
12. 12- A process for the preparation of the compounds according to any of claims 1-10, this method is characterized in that it comprises (a) reacting a compound of the general formula with a compound of the general formula wherein R1-R5 and Q have the meaning set forth in claim 1 and Y represents a starting or separation group, or b) if desired, functionally modify reactive groups present in the reaction product, or c) convert a compound of formula I in a pharmaceutically acceptable salt.
13. 13. A medicament containing a compound according to any of claims 1-10 and a therapeutically inert carrier or vehicle.
14. 14. The use of a compound according to any of claims 1-10 as a medicament, especially in infectious diseases.
15. 15. The use of a compound according to any of claims 1-10 for the production of antibiotically active medicaments.